Osage University Partners has celebrated an exit as migraine treatment developer Satsuma Pharmaceuticals listed on the Nasdaq Global Market following an $82.5m offering.

September started out with news on several life sciences companies about to go public as well as a large acquisition deal of another one of them. This space enjoyed a great number of exits last year and the trend appears on a path to be continued through 2019.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

GSK’s co-investment partnership with Avalon Ventures has borne fruit with the acquisition of celiac treatment developer Sitari Pharmaceuticals.

Express Scripts is set to exit Mango Health having made a strategic investment in the health management app developer two years ago.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.

Lilly Asia Ventures and Baidu Ventures chipped in as part of the latest round for WuXi AppTec-backed drug discovery platform developer Insilico Medicine.

Novartis and Novo helped provide $40m for the autoimmune disease therapy developer that supported its acquisition of joint venture Kanyos Bio.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.